Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

During periods of uncertainty, investors often pay closer attention to businesses that look built to withstand the noise.

Pfizer continues delivering consistent earnings beats, driven by cost-cutting initiatives and improving margins. Learn more ...

Pfizer's stock soared during the coronavirus pandemic because of its COVID-19 vaccine. The world has learned to live with the coronavirus, and Pfizer's stock has plunged as a result. Faced with patent ...

Pfizer is seeking drug development partnerships with Chinese biotech companies as local players gain ground on Western peers. The company aims to broaden its research and development model beyond the ...